Antibiotics Market Size, Share & Trends Report

Antibiotics Market Size, Share & Trends Analysis Report By Action Mechanism (Cell Wall Synthesis Inhibitors, RNA Synthesis Inhibitors), By Drug Class (Penicillin, Cephalosporin), By Type (Branded, Generic), And Segment Forecasts, 2024 - 2030

  • Report ID: GVR-1-68038-149-8
  • Number of Pages: 145
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2022
  • Industry: Healthcare

Market Segmentation

  • Antibiotics Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
    • Cephalosporin
    • Penicillin
    • Fluoroquinolone
    • Macrolides
    • Carbapenems
    • Aminoglycosides
    • Sulfonamides
    • 7-ACA
    • Others
  • Antibiotics Type Outlook (Revenue, USD Million, 2018 - 2030)
    • Branded Antibiotics
    • Generic Antibiotics
  • Antibiotics Action Mechanism Outlook (Revenue, USD Million, 2018 - 2030)
    • Cell Wall Synthesis Inhibitors
    • Protein Synthesis Inhibitors
    • DNA Synthesis Inhibitors
    • RNA Synthesis Inhibitors
    • Mycolic Acid Inhibitors
    • Others
  • Antibiotics Regional Outlook (Revenue, USD Million, 2018 - 2030)
    • North America
      • North America Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
        • Cephalosporin
        • Penicillin
        • Fluoroquinolone
        • Macrolides
        • Carbapenems
        • Aminoglycosides
        • Sulfonamides
        • 7-ACA
        • Others
      • North America Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Branded Antibiotics
        • Generic Antibiotics
      • North America Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
        • Cell Wall Synthesis Inhibitors
        • Protein Synthesis Inhibitors
        • DNA Synthesis Inhibitors
        • RNA Synthesis Inhibitors
        • Mycolic Acid Inhibitors
        • Others
      • U.S.
        • U.S. Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
          • Cephalosporin
          • Penicillin
          • Fluoroquinolone
          • Macrolides
          • Carbapenems
          • Aminoglycosides
          • Sulfonamides
          • 7-ACA
          • Others
        • U.S. Type Outlook (Revenue in USD Million, 2018 - 2030)
          • Branded Antibiotics
          • Generic Antibiotics
        • U.S. Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
          • Cell Wall Synthesis Inhibitors
          • Protein Synthesis Inhibitors
          • DNA Synthesis Inhibitors
          • RNA Synthesis Inhibitors
          • Mycolic Acid Inhibitors
          • Others
      • Canada
        • Canada Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
          • Cephalosporin
          • Penicillin
          • Fluoroquinolone
          • Macrolides
          • Carbapenems
          • Aminoglycosides
          • Sulfonamides
          • 7-ACA
          • Others
        • Canada Type Outlook (Revenue in USD Million, 2018 - 2030)
          • Branded Antibiotics
          • Generic Antibiotics
        • Canada Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
          • Cell Wall Synthesis Inhibitors
          • Protein Synthesis Inhibitors
          • DNA Synthesis Inhibitors
          • RNA Synthesis Inhibitors
          • Mycolic Acid Inhibitors
          • Others
    • Europe
      • Europe Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
        • Cephalosporin
        • Penicillin
        • Fluoroquinolone
        • Macrolides
        • Carbapenems
        • Aminoglycosides
        • Sulfonamides
        • 7-ACA
        • Others
      • Europe Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Branded Antibiotics
        • Generic Antibiotics
      • Europe Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
        • Cell Wall Synthesis Inhibitors
        • Protein Synthesis Inhibitors
        • DNA Synthesis Inhibitors
        • RNA Synthesis Inhibitors
        • Mycolic Acid Inhibitors
        • Others
      • Germany
        • Germany Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
          • Cephalosporin
          • Penicillin
          • Fluoroquinolone
          • Macrolides
          • Carbapenems
          • Aminoglycosides
          • Sulfonamides
          • 7-ACA
          • Others
        • Germany Type Outlook (Revenue in USD Million, 2018 - 2030)
          • Branded Antibiotics
          • Generic Antibiotics
        • Germany Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
          • Cell Wall Synthesis Inhibitors
          • Protein Synthesis Inhibitors
          • DNA Synthesis Inhibitors
          • RNA Synthesis Inhibitors
          • Mycolic Acid Inhibitors
          • Others
      • UK
        • UK Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
          • Cephalosporin
          • Penicillin
          • Fluoroquinolone
          • Macrolides
          • Carbapenems
          • Aminoglycosides
          • Sulfonamides
          • 7-ACA
          • Others
        • UK Type Outlook (Revenue in USD Million, 2018 - 2030)
          • Branded Antibiotics
          • Generic Antibiotics
        • UK Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
          • Cell Wall Synthesis Inhibitors
          • Protein Synthesis Inhibitors
          • DNA Synthesis Inhibitors
          • RNA Synthesis Inhibitors
          • Mycolic Acid Inhibitors
          • Others
      • France
        • France Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
          • Cephalosporin
          • Penicillin
          • Fluoroquinolone
          • Macrolides
          • Carbapenems
          • Aminoglycosides
          • Sulfonamides
          • 7-ACA
          • Others
        • France Type Outlook (Revenue in USD Million, 2018 - 2030)
          • Branded Antibiotics
          • Generic Antibiotics
        • France Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
          • Cell Wall Synthesis Inhibitors
          • Protein Synthesis Inhibitors
          • DNA Synthesis Inhibitors
          • RNA Synthesis Inhibitors
          • Mycolic Acid Inhibitors
          • Others
      • Italy
        • Italy Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
          • Cephalosporin
          • Penicillin
          • Fluoroquinolone
          • Macrolides
          • Carbapenems
          • Aminoglycosides
          • Sulfonamides
          • 7-ACA
          • Others
        • Italy Type Outlook (Revenue in USD Million, 2018 - 2030)
          • Branded Antibiotics
          • Generic Antibiotics
        • Italy Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
          • Cell Wall Synthesis Inhibitors
          • Protein Synthesis Inhibitors
          • DNA Synthesis Inhibitors
          • RNA Synthesis Inhibitors
          • Mycolic Acid Inhibitors
          • Others
      • Spain
        • Spain Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
          • Cephalosporin
          • Penicillin
          • Fluoroquinolone
          • Macrolides
          • Carbapenems
          • Aminoglycosides
          • Sulfonamides
          • 7-ACA
          • Others
        • Spain Type Outlook (Revenue in USD Million, 2018 - 2030)
          • Branded Antibiotics
          • Generic Antibiotics
        • Spain Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
          • Cell Wall Synthesis Inhibitors
          • Protein Synthesis Inhibitors
          • DNA Synthesis Inhibitors
          • RNA Synthesis Inhibitors
          • Mycolic Acid Inhibitors
          • Others
      • Denmark
        • Denmark Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
          • Cephalosporin
          • Penicillin
          • Fluoroquinolone
          • Macrolides
          • Carbapenems
          • Aminoglycosides
          • Sulfonamides
          • 7-ACA
          • Others
        • Denmark Type Outlook (Revenue in USD Million, 2018 - 2030)
          • Branded Antibiotics
          • Generic Antibiotics
        • Denmark Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
          • Cell Wall Synthesis Inhibitors
          • Protein Synthesis Inhibitors
          • DNA Synthesis Inhibitors
          • RNA Synthesis Inhibitors
          • Mycolic Acid Inhibitors
          • Others
      • Sweden
        • Sweden Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
          • Cephalosporin
          • Penicillin
          • Fluoroquinolone
          • Macrolides
          • Carbapenems
          • Aminoglycosides
          • Sulfonamides
          • 7-ACA
          • Others
        • Sweden Type Outlook (Revenue in USD Million, 2018 - 2030)
          • Branded Antibiotics
          • Generic Antibiotics
        • Sweden Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
          • Cell Wall Synthesis Inhibitors
          • Protein Synthesis Inhibitors
          • DNA Synthesis Inhibitors
          • RNA Synthesis Inhibitors
          • Mycolic Acid Inhibitors
          • Others
      • Norway
        • Norway Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
          • Cephalosporin
          • Penicillin
          • Fluoroquinolone
          • Macrolides
          • Carbapenems
          • Aminoglycosides
          • Sulfonamides
          • 7-ACA
          • Others
        • Norway Type Outlook (Revenue in USD Million, 2018 - 2030)
          • Branded Antibiotics
          • Generic Antibiotics
        • Norway Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
          • Cell Wall Synthesis Inhibitors
          • Protein Synthesis Inhibitors
          • DNA Synthesis Inhibitors
          • RNA Synthesis Inhibitors
          • Mycolic Acid Inhibitors
          • Others
    • Asia Pacific
      • Asia Pacific Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
        • Cephalosporin
        • Penicillin
        • Fluoroquinolone
        • Macrolides
        • Carbapenems
        • Aminoglycosides
        • Sulfonamides
        • 7-ACA
        • Others
      • Asia Pacific Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Branded Antibiotics
        • Generic Antibiotics
      • Asia Pacific Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
        • Cell Wall Synthesis Inhibitors
        • Protein Synthesis Inhibitors
        • DNA Synthesis Inhibitors
        • RNA Synthesis Inhibitors
        • Mycolic Acid Inhibitors
        • Others
      • China
        • China Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
          • Cephalosporin
          • Penicillin
          • Fluoroquinolone
          • Macrolides
          • Carbapenems
          • Aminoglycosides
          • Sulfonamides
          • 7-ACA
          • Others
        • China Type Outlook (Revenue in USD Million, 2018 - 2030)
          • Branded Antibiotics
          • Generic Antibiotics
        • China Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
          • Cell Wall Synthesis Inhibitors
          • Protein Synthesis Inhibitors
          • DNA Synthesis Inhibitors
          • RNA Synthesis Inhibitors
          • Mycolic Acid Inhibitors
          • Others
      • Japan
        • Japan Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
          • Cephalosporin
          • Penicillin
          • Fluoroquinolone
          • Macrolides
          • Carbapenems
          • Aminoglycosides
          • Sulfonamides
          • 7-ACA
          • Others
        • Japan Type Outlook (Revenue in USD Million, 2018 - 2030)
          • Branded Antibiotics
          • Generic Antibiotics
        • Japan Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
          • Cell Wall Synthesis Inhibitors
          • Protein Synthesis Inhibitors
          • DNA Synthesis Inhibitors
          • RNA Synthesis Inhibitors
          • Mycolic Acid Inhibitors
          • Others
      • India
        • India Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
          • Cephalosporin
          • Penicillin
          • Fluoroquinolone
          • Macrolides
          • Carbapenems
          • Aminoglycosides
          • Sulfonamides
          • 7-ACA
          • Others
        • India Type Outlook (Revenue in USD Million, 2018 - 2030)
          • Branded Antibiotics
          • Generic Antibiotics
        • India Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
          • Cell Wall Synthesis Inhibitors
          • Protein Synthesis Inhibitors
          • DNA Synthesis Inhibitors
          • RNA Synthesis Inhibitors
          • Mycolic Acid Inhibitors
          • Others
      • Thailand
        • Thailand Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
          • Cephalosporin
          • Penicillin
          • Fluoroquinolone
          • Macrolides
          • Carbapenems
          • Aminoglycosides
          • Sulfonamides
          • 7-ACA
          • Others
        • Thailand Type Outlook (Revenue in USD Million, 2018 - 2030)
          • Branded Antibiotics
          • Generic Antibiotics
        • Thailand Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
          • Cell Wall Synthesis Inhibitors
          • Protein Synthesis Inhibitors
          • DNA Synthesis Inhibitors
          • RNA Synthesis Inhibitors
          • Mycolic Acid Inhibitors
          • Others
      • South Korea
        • South Korea Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
          • Cephalosporin
          • Penicillin
          • Fluoroquinolone
          • Macrolides
          • Carbapenems
          • Aminoglycosides
          • Sulfonamides
          • 7-ACA
          • Others
        • South Korea Type Outlook (Revenue in USD Million, 2018 - 2030)
          • Branded Antibiotics
          • Generic Antibiotics
        • South Korea Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
          • Cell Wall Synthesis Inhibitors
          • Protein Synthesis Inhibitors
          • DNA Synthesis Inhibitors
          • RNA Synthesis Inhibitors
          • Mycolic Acid Inhibitors
          • Others
      • Australia
        • Australia Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
          • Cephalosporin
          • Penicillin
          • Fluoroquinolone
          • Macrolides
          • Carbapenems
          • Aminoglycosides
          • Sulfonamides
          • 7-ACA
          • Others
        • Australia Type Outlook (Revenue in USD Million, 2018 - 2030)
          • Branded Antibiotics
          • Generic Antibiotics
        • Australia Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
          • Cell Wall Synthesis Inhibitors
          • Protein Synthesis Inhibitors
          • DNA Synthesis Inhibitors
          • RNA Synthesis Inhibitors
          • Mycolic Acid Inhibitors
          • Others
    • Latin America
      • Latin America Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
        • Cephalosporin
        • Penicillin
        • Fluoroquinolone
        • Macrolides
        • Carbapenems
        • Aminoglycosides
        • Sulfonamides
        • 7-ACA
        • Others
      • Latin America Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Branded Antibiotics
        • Generic Antibiotics
      • Latin America Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
        • Cell Wall Synthesis Inhibitors
        • Protein Synthesis Inhibitors
        • DNA Synthesis Inhibitors
        • RNA Synthesis Inhibitors
        • Mycolic Acid Inhibitors
        • Others
      • Brazil
        • Brazil Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
          • Cephalosporin
          • Penicillin
          • Fluoroquinolone
          • Macrolides
          • Carbapenems
          • Aminoglycosides
          • Sulfonamides
          • 7-ACA
          • Others
        • Brazil Type Outlook (Revenue in USD Million, 2018 - 2030)
          • Branded Antibiotics
          • Generic Antibiotics
        • Brazil Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
          • Cell Wall Synthesis Inhibitors
          • Protein Synthesis Inhibitors
          • DNA Synthesis Inhibitors
          • RNA Synthesis Inhibitors
          • Mycolic Acid Inhibitors
          • Others
      • Mexico
        • Mexico Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
          • Cephalosporin
          • Penicillin
          • Fluoroquinolone
          • Macrolides
          • Carbapenems
          • Aminoglycosides
          • Sulfonamides
          • 7-ACA
          • Others
        • Mexico Type Outlook (Revenue in USD Million, 2018 - 2030)
          • Branded Antibiotics
          • Generic Antibiotics
        • Mexico Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
          • Cell Wall Synthesis Inhibitors
          • Protein Synthesis Inhibitors
          • DNA Synthesis Inhibitors
          • RNA Synthesis Inhibitors
          • Mycolic Acid Inhibitors
          • Others
      • Argentina
        • Argentina Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
          • Cephalosporin
          • Penicillin
          • Fluoroquinolone
          • Macrolides
          • Carbapenems
          • Aminoglycosides
          • Sulfonamides
          • 7-ACA
          • Others
        • Argentina Type Outlook (Revenue in USD Million, 2018 - 2030)
          • Branded Antibiotics
          • Generic Antibiotics
        • Argentina Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
          • Cell Wall Synthesis Inhibitors
          • Protein Synthesis Inhibitors
          • DNA Synthesis Inhibitors
          • RNA Synthesis Inhibitors
          • Mycolic Acid Inhibitors
          • Others
    • Middle East and Africa
      • Middle East and Africa Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
        • Cephalosporin
        • Penicillin
        • Fluoroquinolone
        • Macrolides
        • Carbapenems
        • Aminoglycosides
        • Sulfonamides
        • 7-ACA
        • Others
      • Middle East and Africa Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Branded Antibiotics
        • Generic Antibiotics
      • Middle East and Africa Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
        • Cell Wall Synthesis Inhibitors
        • Protein Synthesis Inhibitors
        • DNA Synthesis Inhibitors
        • RNA Synthesis Inhibitors
        • Mycolic Acid Inhibitors
        • Others
      • South Africa
        • South Africa Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
          • Cephalosporin
          • Penicillin
          • Fluoroquinolone
          • Macrolides
          • Carbapenems
          • Aminoglycosides
          • Sulfonamides
          • 7-ACA
          • Others
        • South Africa Type Outlook (Revenue in USD Million, 2018 - 2030)
          • Branded Antibiotics
          • Generic Antibiotics
        • South Africa Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
          • Cell Wall Synthesis Inhibitors
          • Protein Synthesis Inhibitors
          • DNA Synthesis Inhibitors
          • RNA Synthesis Inhibitors
          • Mycolic Acid Inhibitors
          • Others
      • Saudi Arabia
        • Saudi Arabia Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
          • Cephalosporin
          • Penicillin
          • Fluoroquinolone
          • Macrolides
          • Carbapenems
          • Aminoglycosides
          • Sulfonamides
          • 7-ACA
          • Others
        • Saudi Arabia Type Outlook (Revenue in USD Million, 2018 - 2030)
          • Branded Antibiotics
          • Generic Antibiotics
        • Saudi Arabia Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
          • Cell Wall Synthesis Inhibitors
          • Protein Synthesis Inhibitors
          • DNA Synthesis Inhibitors
          • RNA Synthesis Inhibitors
          • Mycolic Acid Inhibitors
          • Others
      • UAE
        • UAE Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
          • Cephalosporin
          • Penicillin
          • Fluoroquinolone
          • Macrolides
          • Carbapenems
          • Aminoglycosides
          • Sulfonamides
          • 7-ACA
          • Others
        • UAE Type Outlook (Revenue in USD Million, 2018 - 2030)
          • Branded Antibiotics
          • Generic Antibiotics
        • UAE Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
          • Cell Wall Synthesis Inhibitors
          • Protein Synthesis Inhibitors
          • DNA Synthesis Inhibitors
          • RNA Synthesis Inhibitors
          • Mycolic Acid Inhibitors
          • Others
      • Kuwait
        • Kuwait Drug Class Outlook (Revenue in USD Million, 2018 - 2030)
          • Cephalosporin
          • Penicillin
          • Fluoroquinolone
          • Macrolides
          • Carbapenems
          • Aminoglycosides
          • Sulfonamides
          • 7-ACA
          • Others
        • Kuwait Type Outlook (Revenue in USD Million, 2018 - 2030)
          • Branded Antibiotics
          • Generic Antibiotics
        • Kuwait Action Mechanism Outlook (Revenue in USD Million, 2018 - 2030)
          • Cell Wall Synthesis Inhibitors
          • Protein Synthesis Inhibitors
          • DNA Synthesis Inhibitors
          • RNA Synthesis Inhibitors
          • Mycolic Acid Inhibitors
          • Others

Antibiotics Market Dynamics

Driver: Increasing Prevalence Of Infectious Diseases

The demand for antibiotics is growing significantly, owing to the increasing incidence of infectious diseases. According to WHO, diarrhea is the leading cause of death in children across the globe, and antibiotic intervention is required to prevent morbidity. High prevalence of other infectious diseases, such as lower respiratory infections, pneumonia, malaria, and tuberculosis, is further fueling the market. As of 2019, 229 million cases of malaria were registered worldwide, followed by tuberculosis with 10 million individuals being infected. According to a CDC report in 2019, around 2.8 million people are infected by antibiotic-resistant bacteria every year, and over 35,000 people die due to these infections in the U.S. High incidence of infectious diseases is prompting WHO to take containment efforts, such as R&D initiatives that can boost development of improved antibiotics, supportive regulatory policies to expedite the approval process, and research funding. These factors are expected to propel the antibiotics market over the coming years. Furthermore, emergence of new infections, such as SARS-CoV-2, Zika virus, and Ebola virus, is boosting the development & uptake of antibiotics.

Driver: Growing Collaborations For Development Of Antibiotics

Market players are collaborating for antibiotic development to divide expenses. This is expected to lead to the development of a large number of molecules over the coming years. For instance, in July 2019, Nosopharm announced a partnership with Evotec AG for the development of NOSO-502. It was proposed to be a first-in-class novel antibiotic against Enterobacteriace infections. Furthermore, in April 2019, Forge Therapeutics, Inc. and Basilea Pharmaceutica Ltd. announced a research collaboration and license agreement to develop & market a novel antibiotic. As per the agreement, Basilea would provide an undisclosed amount for the development and receive around USD 167 million sales milestone payment for each antibiotic from the collaboration. Furthermore, increasing number of public-private collaborations, wherein funding and innovative R&D approaches are provided by public agencies to firms developing antibiotics, is expected to boost the product pipeline. For instance, in March 2019, Global Antibiotic Research and Development Partnership (GARDP) announced public-private partnership with Evotec AG for the development of first-in-class antibiotic for treating drug-resistant bacterial infections. Moreover, in December 2018, Eisai Co., Ltd. and Takeda Pharmaceutical Company Limited announced an agreement with GARDP for the development of novel antibacterial compounds.

Restraint: High R&D Cost

Investments in R&D of antibiotics are a financial challenge. The main factors limiting investments include:

  • Relatively low usage of antibiotics, as compared to medication used for managing chronic diseases such as diabetes and hypertension

  • The development of resistance or tolerance to certain bacteria or microorganisms often leads to withdrawal of concerned antibiotic from the market

  • The cost of antibiotics is lower than that of novel drugs Thus, there are high costs involved in the development of antibiotics, which can limit market growth.

What Does This Report Include?

This section will provide insights into the contents included in this antibiotics market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.

Antibiotics market qualitative analysis

  • Industry overview

  • Industry trends

  • Market drivers and restraints

  • Market size

  • Growth prospects

  • Porter’s analysis

  • PESTEL analysis

  • Key market opportunities prioritized

  • Competitive landscape

    • Company overview

    • Financial performance

    • Product benchmarking

    • Latest strategic developments

Antibiotics market quantitative analysis

  • Market size, estimates, and forecast from 2018 to 2030

  • Market estimates and forecast for product segments up to 2030

  • Regional market size and forecast for product segments up to 2030

  • Market estimates and forecast for application segments up to 2030

  • Regional market size and forecast for application segments up to 2030

  • Company financial performance

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

ISO

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon